• Dhesy-Thind B, Pritchard KI, Messersmith H, O'Malley F, Elavathil L, Trudeau M, Breast Cancer Disease Site Group. The role of HER2/neu in systemic and radiation therapy for women with breast cancer: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO); 2006 Nov 10. 50 p. (Evidence-based series; no. 1-17). [120 references]

Patients with HER2/neu-positive breast cancer should be considered for chemotherapy containing an anthracycline instead of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) or melphalan and 5-fluorouracil (PF) chemotherapy.

None provided

The recommendation is supported by randomized trials, meta-analyses, and one practice guideline.

• Dhesy-Thind B, Pritchard KI, Messersmith H, O'Malley F, Elavathil L, Trudeau M, Breast Cancer Disease Site Group. The role of HER2/neu in systemic and radiation therapy for women with breast cancer: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO); 2006 Nov 10. 50 p. (Evidence-based series; no. 1-17). [120 references]

Not applicable: The guideline was not adapted from another source.

2006 Nov 10

Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]

The Program in Evidence-based Care (PEBC) is a Province of Ontario initiative sponsored by Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.

Cancer Care Ontario
Ontario Ministry of Health and Long-Term Care

Provincial Breast Cancer Disease Site Group

The lead authors of this document were asked to report any conflicts of interest. BD, LE, FO, KP, HM, declared that they had no potential conflicts; MT reported receiving per-patient funding for clinical trials.

None available

This summary was completed by ECRI on January 29, 2007. The information was verified by the guideline developer on February 6, 2007.